Complement-Based Drug Development Summit leaderboard
  • Thursday, October 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 22

Author

Pharma Journalist 9091 posts 0 comments

Vedana Launches With $46 Million for Migraine Therapies

Jun 18, 2026
Vedana Therapeutics has emerged from stealth mode with $46 million in Series A financing and ambitious plans to develop next-generation therapies for migraine prevention, targeting…
Read More...

LG AI and D&D Pharmatech Join Forces on Oral Peptides

Jun 18, 2026
LG AI Research and D&D Pharmatech have entered into a strategic partnership aimed at accelerating the development of next-generation oral peptide therapies, highlighting the growing…
Read More...

Jazz and AbCellera Partner on Cancer Antibody Therapies

Jun 18, 2026
Jazz Pharmaceuticals and AbCellera have entered into a new research collaboration aimed at developing next-generation antibody-based treatments for gastrointestinal (GI) cancers and…
Read More...

Biogen to Acquire RayThera in $1 Billion Deal

Jun 18, 2026
Biogen has agreed to acquire private biotechnology company RayThera in a deal valued at up to $1 billion, strengthening the company's growing focus on immunology and expanding its…
Read More...

Insilico Reaches Clinical Milestone for AI-Designed NLRP3 Inhibitor

Jun 17, 2026
Insilico Medicine has announced a significant milestone in the development of its experimental drug candidate ISM8969, marking the first time the therapy has been administered to…
Read More...

Lilly Acquires 4E Therapeutics to Advance Pain Treatments

Jun 17, 2026
Eli Lilly and Company has acquired 4E Therapeutics, a privately held neuroscience biotechnology company focused on developing next-generation therapies for chronic pain, strengthening…
Read More...

Altaris to Acquire Simulations Plus in Cash Deal

Jun 17, 2026
Simulations Plus, a leading provider of model-informed and AI-enabled drug development software and services, has agreed to be acquired by healthcare-focused investment firm Altaris in…
Read More...

UK, US Regulators Launch New Collaboration Programme

Jun 17, 2026
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. Food and Drug Administration (FDA) have announced a new liaison programme aimed at strengthening…
Read More...

Cystic Fibrosis Foundation Backs SpliSense With $13 Million

Jun 17, 2026
SpliSense has secured a funding commitment of up to $13 million from the Cystic Fibrosis Foundation to support the continued clinical development of its lead investigational therapy,…
Read More...

AviadoBio Expands vMiX Gene Therapy Rights Globally

Jun 17, 2026
AviadoBio has expanded its partnership with King’s College London, securing exclusive rights to apply the vMiX™ RNA interference (RNAi) gene-silencing platform across all human…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.